EMEA-001864-PIP02-19
Key facts
| Invented name |
Takhzyro
|
| Active substance |
lanadelumab
|
| Therapeutic area |
Other
|
| Decision number |
P/0140/2020
|
| PIP number |
EMEA-001864-PIP02-19
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Prevention of acquired angioedema attacks
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Takeda Pharmaceuticals International AG Ireland Branch
E-mail: medinfoemea@takeda.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|